CSIMarket
 
Oyster Point Pharma Inc   (OYST)
Other Ticker:  
 
 
Price: $11.1700 $0.02 0.179%
Day's High: $11.2 Week Perf: 0.36 %
Day's Low: $ 11.12 30 Day Perf: -0.09 %
Volume (M): 2,088 52 Wk High: $ 0.00
Volume (M$): $ 23,326 52 Wk Avg: $0.00
Open: $11.16 52 Wk Low: $0.00



 Market Capitalization (Millions $) 300
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -235
 Cash Flow (TTM) (Millions $) -115
 Capital Exp. (TTM) (Millions $) 0

Oyster Point Pharma Inc
Oyster Point Pharma Inc is a pharmaceutical company that focuses on developing and commercializing therapies for diseases affecting the ocular surface. The company specializes in treatments for dry eye disease, a common condition that affects millions of people around the world. Oyster Point Pharma is known for its innovative approach, utilizing neurostimulation technologies to address the underlying causes of dry eye disease. Their goal is to improve the quality of life for patients suffering from this condition by offering effective and innovative treatment options.


   Company Address: 202 Carnegie Center, Suite 106 Princeton 8540 NJ
   Company Phone Number: 382-9032   Stock Exchange / Ticker: NASDAQ OYST
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pharmacyte Biotech Inc

Pharmacyte Biotech Inc Faces Growing Financial Challenges in Fiscal Third Quarter of 2024

The Biotechnology and Pharmaceuticals industry insiders have begun to analyze the third-quarter earnings of 2024. As of now, the industry insiders have observed an operating loss of $-1.868946 million from a particular company, which has not yet disclosed any revenue for the period from November to January 31, 2024. In order to provide some context for the recent performance, it is worth comparing it to the same period in 2023, when the company reported an operating loss of $-1.552983 million.
One of the notable observations from the third quarter of 2024 earnings season, apart from the absence of revenue, is the significant increase in net deficit. The company recorded a net deficit of $-1.401 million, which is considerably higher than the $-0.764 million reported in the corresponding financial reporting period a year ago.

Adverum Biotechnologies Inc

2 Adverum Biotechnologies Inc Defies Market Expectations with Strong Fiscal Performance

Adverum Biotechnologies Inc, a leading biotechnology and pharmaceutical company, has experienced a decrease in its stock by -19.05% in the preceding 30 days. Despite this decline, the year-to-date performance of the company stands at an impressive 105.29%. Currently trading on the NASDAQ, Adverum Biotechnologies Inc's stock is 31.8% above its 52-week average.
During the earnings season from October to December 31, 2023, shareholders did not expect any moderations in the company's top-line performance. However, they were pleasantly surprised by the positive operating deficit of $-26.158 million during the same period. This improvement from the previous quarter's operating deficit of $-33.94 million has increased analysts' confidence in Adverum Biotechnologies Inc.

Zeo Scientifix Inc

Very balanced growth for BPSR during the November to January 31 2024 three months

Zeo Scientifix Inc has shown promising growth in its recent financial results, despite reporting a deficit per share of $-0.17 for the span ending January 31, 2024. This is a significant improvement from the deficit of $-2.287 million in the same period a year ago. The company's revenue also saw a healthy increase of 7.828% to $1.15 million, showing strong growth potential.
One key highlight of the financial report is the notable increase in inventories and supplies, which now stand at $0.3 million. This indicates that the company is investing in its operations and preparing for future growth. Additionally, the decrease in accounts receivable compared to the previous year suggests that the company is effectively managing its cash flow and collections.

Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year.
Unlike many other entities in the Biotechnology and Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc Reports Operating Deficit of $-18.2 Million in Fourth Quarter of 2023

In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022.
The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.






 

Oyster Point Pharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com